A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization

R Liu, J Wang, Y Shao, X Wang, H Zhang, L Shuai… - Antiviral research, 2018 - Elsevier
Middle East respiratory syndrome coronavirus (MERS-CoV) has been a highly threatening
zoonotic pathogen since its outbreak in 2012. Similar to SARS-CoV, MERS-CoV belongs to …

Cross-protection against MERS-CoV by prime-boost vaccination using viral spike DNA and protein

J Choi, J Goo, E Yang, DI Jung, S Lee, S Rho… - Journal of …, 2020 - Am Soc Microbiol
Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory
illness and has a high mortality of∼ 34%. However, since its discovery in 2012, an effective …

Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus

Y Deng, J Lan, L Bao, B Huang, F Ye… - Emerging Microbes & …, 2018 - Taylor & Francis
The persistent public health threat of infection with Middle East respiratory syndrome
coronavirus (MERS-CoV) highlights the need for an effective and safe MERS-CoV vaccine …

Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice

C Wang, X Zheng, W Gai, G Wong, H Wang, H Jin… - Antiviral research, 2017 - Elsevier
Middle East respiratory syndrome coronavirus (MERS-CoV) has continued spreading since
its emergence in 2012 with a mortality rate of 35.6%, and is a potential pandemic threat …

[HTML][HTML] Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein

J Goo, Y Jeong, YS Park, E Yang, DI Jung, S Rho… - Virus research, 2020 - Elsevier
Abstract Middle East Respiratory Syndrome coronavirus (MERS-CoV) causes severe
pulmonary infection, with∼ 35% mortality. Spike glycoprotein (S) of MERS-CoV is a key …

Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than …

C Ma, Y Li, L Wang, G Zhao, X Tao, CTK Tseng, Y Zhou… - Vaccine, 2014 - Elsevier
Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) was originally identified
in Saudi Arabia in 2012. It has caused MERS outbreaks with high mortality in the Middle …

[HTML][HTML] Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein

SS Al-Amri, AT Abbas, LA Siddiq, A Alghamdi… - Scientific reports, 2017 - nature.com
MERS-coronavirus is a novel zoonotic pathogen which spread rapidly to> 25 countries since
2012. Its apparent endemicity and the wide spread of its reservoir host (dromedary camels) …

MERS-CoV spike nanoparticles protect mice from MERS-CoV infection

CM Coleman, T Venkataraman, YV Liu, GM Glenn… - Vaccine, 2017 - Elsevier
Abstract The Middle East respiratory syndrome coronavirus (MERS-CoV) was first
discovered in late 2012 and has gone on to cause over 1800 infections and 650 deaths …

Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies

F Song, R Fux, LB Provacia, A Volz… - Journal of …, 2013 - Am Soc Microbiol
Middle East respiratory syndrome coronavirus (MERS-CoV) has recently emerged as a
causative agent of severe respiratory disease in humans. Here, we constructed recombinant …

[HTML][HTML] Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle …

MH Kim, HJ Kim, J Chang - PLoS One, 2019 - journals.plos.org
Middle East respiratory syndrome coronavirus (MERS-CoV) causes an acute and severe
lower respiratory illness as well as vomiting, diarrhea, and renal failure. Because no …